加拿大安大略省老年人地舒单抗使用情况:患者特征、持续治疗及间断后恢复治疗
研究纳入加拿大安大略省2012年2月至2015年3月启动地舒单抗的46797例≥66岁老年人,随访至2016年3月。社区居住者较长期护理机构患者更年轻(平均78.5岁 vs 86.6岁)、髋部骨折患病率更低(3% vs 10%),但骨密度检测率更高(62% vs 5%)。持续治疗≥3年者占48%,停药后3.6年内59%恢复治疗。
要点
- 共纳入46797例老年人,97%为女性,13%居住于长期护理机构。
- 持续治疗≥2年、≥3年、≥4年者分别占59%、48%、38%。
- 停药后3.6年内59%恢复地舒单抗治疗,长期护理机构患者恢复比例更高(76% vs 57%)。
核心结论
- 地舒单抗在安大略省的使用率稳步上升,但鉴于其药代动力学高度可逆、停药后骨折风险迅速增加,持续治疗情况仍令人担忧。
- 超过80%的患者有口服双膦酸盐治疗史,该药在停用地舒单抗后可能仍滞留于骨内,因此需更好地了解地舒单抗在真实世界使用者中的安全性和有效性。
研究设计与样本
- 研究为回顾性队列分析,利用加拿大安大略省医疗和药房索赔数据,纳入2012年2月至2015年3月启动地舒单抗的≥66岁老年人,随访至2016年3月。
- 共识别46797例患者(月均1263例,标准差187),按社区居住和长期护理机构居住分层。
- 采用Kaplan-Meier曲线估计持续治疗及停药(间隔>90天)后恢复治疗情况。
主要发现
- 患者中97%为女性,13%居住在长期护理机构。
- 社区居住患者较长期护理机构患者更年轻(平均年龄78.5岁 vs 86.6岁),髋部骨折患病率更低(3% vs 10%),但骨密度检测率更高(62% vs 5%)。
- 82%的患者既往使用过骨质疏松药物,其中99%使用过口服双膦酸盐。
- 社区居住与长期护理机构患者的持续治疗情况相似:持续≥2年者59%,≥3年者48%,≥4年者38%。
- 长期护理机构患者停药后恢复地舒单抗治疗的比例高于社区居住患者(76% vs 57%)。
关键数值与推荐
- 持续治疗≥2年、≥3年、≥4年的患者分别占59%、48%、38%。
- 停药(间隔>90天)后恢复治疗的患者占59%,恢复时间窗为3.6年内。
- 长期护理机构患者停药后恢复治疗比例为76%,社区居住患者为57%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We studied 46,797 older adults who initiated denosumab in Ontario, Canada. Patient characteristics remained relatively stable over time and aligned with public reimbursement restrictions. Almost half of patients persisted with therapy for at least 3 years. Fifty-nine percent of patients who discontinued denosumab returned to treatment within 3.6 years. INTRODUCTION: The purpose of this study was to describe the characteristics of patients who initiated denosumab and estimate persistence with therapy. METHODS: We identified older adults (aged ≥ 66 years) in Ontario who initiated denosumab between 2012/02 and 2015/03 and followed them to 2016/03. Patient characteristics were summarized using medical and pharmacy claims in the year before starting denosumab and osteoporosis drug use considered since 1996/10. Persistence with denosumab and return after discontinuation (> 90-day gap) were estimated using Kaplan-Meier curves. Analyses were stratified by community and long-term care (LTC) residence. RESULTS: We identified 46,797 patients (monthly mean = 1263, SD = 187); 97% female, 13% LTC. Community-dwelling patients had a higher prevalence of bone mineral density testing (62% vs. 5%), yet were younger (mean age 78.5 vs. 86.6 years) and had lower prevalence of hip fractures (3% vs. 10%) compared to LTC patients. Eighty-two percent of patients had used osteoporosis medications in the past; 99% of whom took an oral bisphosphonate. Persistence was similar between community-dwelling and LTC patients: 59% persisted ≥ 2 years, 48% ≥ 3 years, and 38% ≥ 4 years, yet a larger proportion of LTC patients returned to denosumab after discontinuation (76% vs. 57%). CONCLUSIONS: Denosumab utilization is increasing at a steady rate in Ontario. However, persistence remains a concern given the highly reversible pharmacokinetic profile of denosumab that results in a rapid increased fracture risk following discontinuation. Over 80% of patients had a history of oral bisphosphonate therapy, which may persist in bone despite discontinuing denosumab. Consequently, better understanding of denosumab safety and effectiveness among real-world users is important.
引用
- Ban JK, Hao BB, McCarthy L, et al. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap. Osteoporos Int. 2019. PMID: 31317248. doi:10.1007/s00198-019-05051-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。